histone deacetylase 3

A compound being developed to treat Friedreich's ataxia specifically targets an unwanted molecular brake

posted on September 29, 2009 - 11:32am
Scientists at the Scripps Research Institute in La Jolla, Calif., and the Repligen Corporation in Waltham, Mass., have identified the precise biochemical brake that limits production of a needed protein in Friedreich's ataxia (FA) and determined that this brake is specifically targeted by an experim

New content is being added every day. Please check back again.